Cure My Disease

Don't miss your cure!

 Log in / Sign up

Single-Cell tech could unlock secrets of a highly effective vaccine

NCT ID NCT03458780

Completed Knowledge-focused Sponsor: Rockefeller University Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This pilot study tests a new technology called inDrop RNA-Seq to analyze individual immune cells in detail. Researchers will use it to study how healthy adults respond to the yellow fever vaccine, which is known to be very effective. The goal is to identify the specific cell types and genes that drive a strong immune response, which could help improve future vaccines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
yellow fever vaccine (YF-Vax)
What this could lead to
If successful, this could reveal which cell types and genes are key for a strong vaccine response, potentially guiding better vaccine design.
What could go wrong
This is a very small pilot study with only 6 participants, so findings may not apply broadly. The technology is also new and unproven for this purpose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

yellow fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • The Rockefeller University

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.